This is the authors' abstract. We don't add key points for this paper.
experimental validation can uncover clinically relevant cell populations and regulatory mechanisms within complex tumor ecosystems.Kang et al. focused on immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy (10). Their study revealed that patients who developed irAEs exhibited enhanced myeloid inflammatory activity and interferon-associated immune activation before treatment initiation. An immune-feature-based model derived from peripheral blood profiles was developed to identify individuals at higher risk. In addition, perturbation-based analysis was used to prioritize candidate compounds, several of which were experimentally validated for their ability to suppress IFN-γrelated signaling pathways (10). This study connects risk prediction with potential therapeutic intervention and provides a framework for early identification and management of immunotherapy-associated toxicity.Two studies applied interpretable machine learning approaches to prognostic prediction in critically ill cancer patients. Xia et al. developed a model for predicting in-hospital mortality among patients with lung cancer in the MIMIC-IV database (11). Li et al. established a 28-day mortality prediction model for critically ill patients with liver cancer and further analyzed the contributions of acute physiological disturbances, liver and kidney dysfunction, and comorbidity burden (12). These models relied primarily on routinely collected clinical variables available during early hospitalization, highlighting their potential accessibility in clinical settings. However, independent validation across multiple institutions and prospective evaluation remain essential before such models can be integrated into routine clinical decision-making.AI is also expanding its role in supportive cancer care. Wen et al. analyzed data from 12,431 patients across 58 medical centers and developed prediction models for the efficacy and safety of recombinant human interleukin-11 therapy in cancer treatmentrelated thrombocytopenia (13). The study incorporated an external validation cohort and applied SHAP analysis to identify factors associated with treatment response and adverse events (13). These findings suggest that personalized medicine extends beyond anticancer drug selection and may also improve supportive care strategies and toxicity management.patients with extensive-stage small-cell lung cancer receiving chemotherapy combined with immunotherapy. Radiotherapy was associated with additional tumor reduction and improved survival outcomes; however, these differences were attenuated after weighting adjustment (14). Therefore, these findings should be interpreted as evidence supporting patient selection and prospective trial design rather than as a replacement for randomized controlled studies.The Research Topic also expands the scope of precision oncology data beyond Future efforts will require deeper integration of multi-omics, imaging, and longitudinal clinical data, together with improved model calibration, cross-center generalizability, fairness, and compatibility with clinical workflows. Ultimately, the value of AI in precision oncology will depend not only on computational performance but also on its ability to generate biologically testable hypotheses and enable actionable clinical decisions (17,18). By bridging data-driven discovery and clinical implementation, AI has the potential to become an integral component of next-generation precision cancer therapies (18).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: